Last updated: June 6, 2026
Suppliers for DIANEAL PD-2 with Dextrose 4.25% in Plastic Container (4.25% PD-2)
DIANEAL PD-2 W/ DEXTROSE 4.25% in plastic container is supplied in the U.S. market primarily by Baxter and is marketed under the Baxter portfolio for peritoneal dialysis solutions. The commercial and regulatory supply chain typically includes (1) Baxter as the marketing authorization holder and primary distributor to wholesalers and dialysis providers, and (2) contract logistics and distribution partners operating under Baxter’s distribution footprint.
Who supplies DIANEAL PD-2 with dextrose 4.25% in plastic containers in the U.S.?
Primary supplier / marketer: Baxter Healthcare Corporation (DIANEAL brand; peritoneal dialysis solutions).
DIANEAL PD-2 solutions are distributed through the standard pharmaceutical wholesaler channel into hospitals, dialysis clinics, and home therapy providers.
What company is the NDA holder for DIANEAL PD-2 solutions?
Baxter is the NDA/marketing authorization holder for the DIANEAL peritoneal dialysis solution line in the U.S. (brand-level product ownership in the Orange Book and FDA label reflects Baxter’s role as the listed applicant/holder for the marketed products).
What distribution partners supply DIANEAL PD-2 to hospitals and dialysis clinics?
DIANEAL PD-2 is generally supplied through U.S. pharmaceutical distribution networks using wholesalers and logistics providers that operate under purchase contracts with Baxter or Baxter’s affiliates. In practical procurement terms, suppliers at delivery points are usually:
- Major pharmaceutical wholesalers supplying hospital and clinic accounts
- Dialysis product distributors used by provider networks
- Home infusion and home therapy logistics partners for home peritoneal dialysis programs
What is the Orange Book status of DIANEAL PD-2 W/ DEXTROSE 4.25% in plastic container?
DIANEAL PD-2 products are typically protected and managed as brand pharmaceutical products with FDA label-listed status; the Orange Book listing identifies the NDA product and any associated patent terms for exclusivity and patent enforcement (if applicable). DIANEAL products have historically had manufacturer and patent listings reflected in the Orange Book for specific NDA entries.
Who are the generic or alternative supplier risks for DIANEAL PD-2?
For peritoneal dialysis solutions, supply risk and substitution risk come from:
- Competing branded PD solution manufacturers
- Authorized generics or equivalent-strength PD solutions
- Importation channel alternatives (where available)
- Form/packaging constraints: plastic container format is a key procurement spec
Which companies make peritoneal dialysis solutions similar to DIANEAL PD-2 4.25% dextrose?
The peer supplier set for peritoneal dialysis solutions typically includes manufacturers of PD fluids used for CAPD/APD, with multiple companies competing by configuration (bag type, strength, lactate/bicarbonate solutions, glucose concentrations, and composition). In procurement and formulary selection, “DIANEAL PD-2 4.25% in plastic container” is treated as a specific strength and container spec rather than interchangeable with all PD fluids.
What dosing strengths and container formats affect supplier selection?
Supplier capability is strongly driven by:
- Dextrose concentration (here: 4.25%)
- PD solution type (here: PD-2 product line)
- Bag/container type (here: plastic container)
- Therapy system compatibility (home cycler vs manual exchanges, depending on clinic protocol)
How long do supply contracts typically last for DIANEAL PD-2 PD solutions?
Hospital and dialysis clinic purchasing contracts for PD solutions are commonly structured as:
- Multi-quarter to annual agreements with pricing tiers
- Automatic replenishment schedules
- Allocation terms during supply constraints
What manufacturing and packaging/IP barriers affect alternate supply for DIANEAL PD-2?
Alternate suppliers must align to:
- FDA-labeled composition for that specific strength
- Plastic container compatibility with delivery systems
- Quality systems aligned with sterile solution manufacturing and container integrity testing
What regulatory status affects supplier eligibility for DIANEAL PD-2?
Only manufacturers with FDA authorization to market the specific PD solution strengths and container formats can supply direct substitutes. Supplier eligibility for alternative products depends on:
- FDA approval status (or lawful marketing status)
- Label matching to the procurement spec (strength, osmolarity ranges, buffer system, and bag/container format)
Key Takeaways
- DIANEAL PD-2 with dextrose 4.25% in plastic containers is primarily supplied in the U.S. by Baxter as the brand marketer and dominant supply channel source.
- Procurement is driven by strength (4.25%), product line (PD-2), and container format (plastic bag), which narrow substitution options.
- Alternative sourcing is limited to other PD solution suppliers that match FDA-labeled composition and packaging format, and that meet dialysis provider contracting requirements.
FAQs
1. Who is the main distributor of DIANEAL PD-2 4.25% dextrose plastic bags?
Baxter supplies through the U.S. pharmaceutical wholesaler and dialysis distribution channel into provider accounts.
2. Are DIANEAL PD-2 4.25% solutions interchangeable with other glucose PD fluids?
No. Substitution is constrained by FDA-labeled strength and specific product line/bag format requirements used by dialysis providers.
3. What matters more for procurement: the dextrose percentage or the PD-2 designation?
Both. Procurement specs usually require the exact labeled strength and the PD-2 product identity to ensure compatibility with clinic protocols.
4. Do plastic containers create unique supplier eligibility requirements?
Yes. Bag/container format is part of the product specification that limits substitution among PD fluid manufacturers.
5. What is the most common sourcing route for DIANEAL PD-2 in hospitals?
Purchase through established pharmaceutical wholesalers with contracting tied to Baxter’s brand availability.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. Food and Drug Administration. Drug Label (DIANEAL PD-2 with Dextrose 4.25% in Plastic Container). FDA.
